Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2022-006329 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Kui-Sheng Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Jingjiang People's Hospital, Jingjiang, Jiangsu, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hyperbaric Oxygenation, Liver Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Recently, we followed the report by Yang et al that hyperbaric oxygen facilitates teniposide-induced The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway(cGAS-STING) activation to enhance the antitumor efficacy of an anti-PD-1 antibody in Hepatocellular carcinoma (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Jingjiang People's Hospital, Jingjiang, Jiangsu, China.
- Department of General Surgery, Jingjiang People's Hospital, Jingjiang, Jiangsu, China yks050605@163.com.
Zitieren
APA
Yang, K. S., Xu, C. Q., & Lv, J. (2023). Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006329
Vancouver
Yang KS, Xu CQ, Lv J. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006329
BibTeX
@article{Yang2023,
author = {Yang, Kui-Sheng and Xu, Chuan-Qi and Lv, Jian},
title = {Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2022-006329}
}
EUVIMED